Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04756336
Other study ID # C20-109-07
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date March 5, 2021
Est. completion date July 1, 2021

Study information

Verified date February 2021
Source Pharma Holdings AS
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An Open label Phase II//proof of concept-study to demonstrate if percutaneous application of LTX-109 in a gel vehicle is a safe treatment of Hidradenitis suppurativa and to identify clinical response to intervention, as well to identify if covariates such as age, disease duration, smoking state and BMI influence patient reported measures.


Description:

It is unclear whether bacterial colonization in hidradenitis suppurativa/acne inversa (HS) comprises a primary cause, triggering factor or secondary phenomenon of the disease pathogenesis. Studies imply that aberrant immune responses play a role involving both the innate and adaptive immune system, however the clinical picture of HS lesions appears reminiscent of bacterial infection, e.g. due to intense inflammation and malodorous discharge. Recent microbiological studies indicate certain bacterial species are associated with mature HS lesions. It is demonstrated a significant high occurrence of large bacterial biofilms (aggregates > 50 μm in diameter) in tunnels. In total, an array of studies point to a potential involvement of a specific microbiota in the pathogenesis of HS. The antimicrobial effect of LTX-109 can reduce or eradicate bacterial growth and thus also the inflammatory stimulus of hidradenitis. The antiinflammatory effects of LTX-109 through inhibition of bacterial colonization or infection can prevent rupture and proliferation of follicular material in the dermis. Hidradenitis in more advanced stages can be targeted with this investigational drug. However, it is not reasonable to expect that chronic, longstanding inflammation and sinus formation will heal in six week of intervention. Therefore, patients with most severe activity (Hurley stadium III) or with widespread disease (>5 palm units) will not be included in the study. The investigator wishes to document whether LTX-109 is an effective compound on hidradenitis. Evidence-based medical treatment of mild disease consists of topical antibiotics (Clindamycin). Systemic antibiotics (Tetracycline) is used for disease that is more widespread. In other parts of Europe, but not recommended in Norway due to the fear of over-usage of Rifampicin, patients who fail to exhibit response to treatment or have a moderate-to-severe disease, systemic Clindamycin 300 in combination with Rifampicin can be given. Patients failing to exhibit response to treatment options mentioned above or for moderate-to-severe disease, biologic therapy (Adalimumab) can be administered. Interestingly, Bacterial growth in HS patients has shown a high level of resistance to antibiotics, including rifampicin, clindamycin and tetracyclines, cited as an empiric choice in HS therapeutic guidelines. Therefore, other treatment options targeting bacteria in HS is warranted. It would be important to demonstrate whether the lytic peptidomimetic LTX-109 may be effective in the condition as the treatment has apparent benefits, such as a good safety profile, easy self-administered application and no known risk of development of resistance to the Investigational Medicinal Product. The study will be open label on 16 patients. Treatment will be twice daily application on affected lesions for 6 weeks. Followup after end of treatment will be 3 months.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date July 1, 2021
Est. primary completion date July 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients with active hidradenitis in the stage I-II according to Hurley's classification. 2. Patients are referred to a dermatology out-patient clinic or patients already in an established treatment program, where there is indication for new or different treatment, or surgical intervention. 3. Patients must have typical affection of the disease of either axillae, groins, and/or perigenital/perianal area 4. Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to international guidelines, and national/local regulations. 5. For women in fertile age: Concents to use highly effective contraception until the end of the study Exclusion Criteria: 1. Patients in need of emergency medical or surgical treatment of hidradenitis 2. Subjects must not have used the following HS treatments within the specified timeframe prior to Baseline Visit: 1. Systemic therapy for HS, including but not limited to corticosteroids, antibiotics, dapsone or retinoids within 4 weeks 2. Targeted biologic treatments (refer to within 5 half-lives [if known]) or within 12 weeks, whichever is longer. 3. Topical treatments with antibiotics, including but not limited to clindamycin within 4 weeks 3. Patients with hidradenitis affecting larger areas (>5 palm units) 4. Patient does not agree to be registered in the national quality register for HS 5. Pregnant or lactating women 6. Any reason why, in the opinion of the investigator, the patient should not participate

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
LTX-109 gel, 3% w/w
The drug is applied to affected lesions according to treatment regimen

Locations

Country Name City State
Norway University Hospital of North Norway Tromsø

Sponsors (2)

Lead Sponsor Collaborator
Pharma Holdings AS University Hospital of North Norway

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Investigator assessed signs for local reactions to the Investigational Medicinal Product Investigator assessment of signs of local reactions End point analysis at 6 weeks
Primary Patient reported symptoms for local reactions to the Investigational Medicinal Product Patient reported symptoms for local reactions End point analysis at 6 weeks
Secondary Change in Investigator assessment of condition from Baseline Investigator assessed change in condition assessed by Hidradenitis suppurativa score (Sartorius) from Baseline to week 6 End point analysis after 6 weeks
Secondary Change in Investigator assessment disease activity from Baseline Investigator assessed change in disease activity assessed by Hurley's stage division from Baseline to week 6 End point analysis after 6 weeks
Secondary Change in Investigator assessed number of lesions from Baseline Investigator assessed change in number of inflammatory lesions from Baseline to week 6 assessed by International Hidradenitis Suppurativa Severity Score System End point analysis after 6 weeks
Secondary Change in Patient recorded Dermatology Life Quality Index (DLQI) from Baseline Change in patient recorded Dermatology Life Quality Index (DLQI) from Baseline to week 6 Endpoint analysis at week 6
Secondary Change in Patient recorded Visual Analog Score for pain (VAS) from Baseline Change in patient recorded Visual Analog Score for pain (VAS) from Baseline to week 6 Endpoint analysis at week 6
See also
  Status Clinical Trial Phase
Completed NCT02904902 - Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa Phase 3
Completed NCT03628924 - A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) Phase 2
Not yet recruiting NCT05531747 - Replicative Stress in Hair Follicle Stem Cells and Pathogeny of Hidradenitis Suppurativa N/A
Recruiting NCT06028230 - A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Completed NCT03275870 - Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Phase 1/Phase 2
Completed NCT03248531 - A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. Phase 2
Withdrawn NCT04100083 - Spironolactone for Hidradenitis Suppurativa Phase 4
Completed NCT00329823 - Etanercept in Hidradenitis Suppurativa Phase 2
Recruiting NCT05710393 - Hidradenitis - an Analysis of Genetic Traits and Linkages in Families
Completed NCT04019041 - A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa Phase 2
Completed NCT05286567 - A Double-blind Placebo-controlled Randomized Trial Evaluating the Efficacy and Safety of a Novel HSP90 Inhibitor (RGRN-305) in the Treatment of Moderate to Severe Hidradenitis Supppurativa. Phase 1
Withdrawn NCT03929835 - Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa Phase 2
Terminated NCT04325607 - Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa N/A
Terminated NCT03238469 - Microwave Ablation in Mild Axillary Hidradenitis Suppurativa N/A
Completed NCT04449354 - HidraWear AX HS Study N/A
Recruiting NCT06123429 - Mindfulness in Hidradenitis Suppurativa N/A
Recruiting NCT05934825 - Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa Phase 1/Phase 2
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting NCT06046729 - A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Phase 2
Recruiting NCT04246372 - Tofacitinib for Immune Skin Conditions in Down Syndrome Phase 2